Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230002 | 0.92 | NAAA (0.52) | NAAATSHRALDH1A1L3MBTL1TDP1 | |
| SCHEMBL1790956 | 0.90 | TSHR (0.45) | NAAATSHRALDH1A1L3MBTL1TDP1 | |
| SCHEMBL6945037 | 0.84 | NAAA (0.47) | NAAATSHRALDH1A1L3MBTL1TDP1 | |
| SCHEMBL4067507 | 0.82 | ALDH1A1 (0.50) | TSHRALDH1A1L3MBTL1TDP1MAPK1 | |
| SCHEMBL3230007 | 0.82 | NAAA (0.52) | NAAATSHRALDH1A1L3MBTL1TDP1 | |
| SCHEMBL8506264 | 0.81 | TSHR (0.54) | NAAATSHRALDH1A1L3MBTL1TDP1 | |
| SCHEMBL13195787 | 0.81 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1TDP1MAPK1LMNA | |
| SCHEMBL7669911 | 0.81 | TDP1 (0.49) | NAAATSHRALDH1A1L3MBTL1TDP1 | |
| SCHEMBL3543222 | 0.80 | LMNA (0.53) | NAAATSHRALDH1A1L3MBTL1TDP1 | |
| SCHEMBL26648126 | 0.79 | ALDH1A1 (0.50) | NAAATSHRALDH1A1L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9707246-B2 | Substituted (3S,11AR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11A-hexahydro[1,3]oxazolo[3,2-A]pyrido[1,2-D]pyrazine-8-carboxamides as HIV agents | SHIONOGI & CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| EP-2660239-B1 | CHEMICAL COMPOUNDS AS SYNTHETIC INTERMEDIATES | VIIV HEALTHCARE CO (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-2320909-B1 | CHEMICAL COMPOUNDS | VIIV HEALTHCARE CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150335667-A1 | CHEMICAL COMPOUNDS | SHIONOGI & CO (JP) | 2015-11-26 | — | — | US | disclosed |
| US-9133216-B2 | (3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-9 and/or (3S,11aR)-6-[(phenymethyl)oxy]-8-bromo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-10 | SHIONOGI & CO., LTD. (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20150183803-A1 | (3S,11aR)-6-[(PHENYLMETHYL)OXY]-3-METHYL-2,3,11,11a-TETRAHYDROOXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-5,7-DIONE OF THE FORMULA P-9 AND/OR (3S,11aR)-6-[(PHENYLMETHYL)OXY]-8-BROMO-3-METHYL-2,3,11,11a-TETRAHYDROOXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-5,7-DIONE OF THE FORMULA P-10 | SHIONOGI & CO (JP) | 2015-07-02 | — | — | US | disclosed |
| US-9012650-B2 | Substituted (3S, 11aR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides of formula (I) useful as HIV agents | SHIONOGI & CO., LTD. (JP) | 2015-04-21 | — | — | US | disclosed |
| US-8981129-B2 | 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one of the formula P-3 and/or 2-[(E)-2-phenylethenyl]-3-[(phenylmethyl)oxy]-4H-Pyran-4-one of the formula P-4 | SHIONOGI & CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8940912-B2 | 4-oxo-3-[(phenylmethyl)oxy]-4H-pyran-2-carboxylic acid | VIIV HEALTHCARE COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140256679-A1 | CHEMICAL COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-8580967-B2 | Methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-carboxylate and processes for the preparation thereof | SHIONOGI & CO., LTD. (JP) | 2013-11-12 | — | — | US | disclosed |
| EP-2660239-A1 | Chemical compounds as synthetic intermediates | VIIV Healthcare Company (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20110183940-A1 | CHEMICAL COMPOUNDS | VIIV HEALTHCARE COMPANY | 2011-07-28 | — | — | US | disclosed |
| EP-2320909-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010011814-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-0973768-B1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-07-09 | — | — | EP | disclosed |
| US-6407129-B1 | INJECTABLE QUATERNIZED SALT FUNGICIDES; WATER SOLUBILITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1120116-A1 | ANTIMYCOTIC DRUG COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 2001-08-01 | — | — | EP | disclosed |
| EP-0973768-A1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998043970-A1 | AZOLE COMPOUNDS, THEIR PRODUCTION AND THEIR USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256679-A1 | CHEMICAL COMPOUNDS | PAICS, APRT, SAMHD1 | NAAA 333/4885TSHR 4702/4885ALDH1A1 1616/4885 |
| US-20150183803-A1 | (3S,11aR)-6-[(PHENYLMETHYL)OXY]-3-METHYL-2,3,11,11a-TETRAHYDROOXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-5,7-DIONE OF THE FORMULA P-9 AND/OR (3S,11aR)-6-[(PHENYLMETHYL)OXY]-8-BROMO-3-METHYL-2,3,11,11a-TETRAHYDROOXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-5,7-DIONE OF THE FORMULA P-10 | CDK9, INTS9, DPYD | NAAA 4270/4885TSHR 3225/4885ALDH1A1 1023/4885 |
| US-20150335667-A1 | CHEMICAL COMPOUNDS | PAICS, APRT, SAMHD1 | NAAA 333/4885TSHR 4702/4885ALDH1A1 1616/4885 |
| US-20110183940-A1 | CHEMICAL COMPOUNDS | PAICS, APRT, SAMHD1 | NAAA 333/4885TSHR 4702/4885ALDH1A1 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.